Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427973 · ClinicalTrials.gov registry record · Phase 2
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00427973: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00427973 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427973, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Primary Outcome
Progression is defined as a 20% increase in the sum of the of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions by conventional RECIST based criteria, or death, which ever comes first. This design yields at least 90% power to detect a true 3-month PFS rate of at least 69%.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- PROCEDURE computed tomography
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- DRUG cediranib maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Why NCT00427973 stopped before completion
NCT00427973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00427973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00427973 about?
NCT00427973 is a clinical study titled "AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer". This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
What is the current status of trial NCT00427973?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2009-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00427973?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), computed tomography (PROCEDURE), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00427973?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00427973's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia